Disclosed herein are urushiol-containing epicutaneous patches comprising a support material and a urushiol-containing film on a surface of the support material. A surface of the support material is coated with the urushiol-containing film. Also described herein are test panels comprising urushiol-containing epicutaneous patches of varying urushiol content. The test panels can be employed in methods to assess subject sensitivity to urushiol, to determine a dose-response relationship to varying doses of urushiol, and to assess efficacy of treatments to prevent or inhibit urushiol-induced contact dermatitis in a subject.

Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

The present invention relates to methods for removal of dead tissue from wounds or skin using topical nitric oxide donor devices and/or compositions. In one embodiment, the present invention relates to a transdermal patch device that is designed to deliver nitric oxide. In another embodiment, the present invention relates to one or more devices and/or compositions that are designed to deliver nitric oxide and optionally one or more other compounds, where such devices/compositions include, without limitation, bandages, layered bandages, adhesive bandages, transdermal patches, creams, ointments, or a any combination of two or more thereof.

Embodiments relate to a formulation comprising a particle comprising a turmeric oleoresin or a curcumin removed turmeric oleoresin or a turmeric oil or combination thereof wherein the composition is water-soluble and therapeutically safe, wherein the composition does not contain a pH buffer, and wherein the composition further comprises a curcuminoid.

A patch comprising a support layer and an adhesive agent layer, wherein the adhesive agent layer comprises at least one drug selected from the group consisting of emedastine and pharmaceutically acceptable salts thereof, at least one adhesive agent selected from the group consisting of rubber-based adhesive agents and silicone-based adhesive agents, and an alkali metal fumarate as a cohesive force-improving agent for the adhesive agent layer.

Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound.

Pharmaceutical compositions and methods for treating and/or preventing and/or control of Parkinson's Disease and/or related symptoms in a patient.

The present invention relates to the use of an additive in a transdermal therapeutic system with an active agent-containing layer in the form of a biphasic layer having a hydrophilic inner phase and a hydrophobic outer phase, in which the inner phase includes the additive and an active agent dissolved therein. The additive has a higher affinity to water than to the active agent and controls the permeation rate of the active agent in a manner which is independent from its concentration in the biphasic layer, with the maintenance of the permeation rate being proportional to the amount of active agent in the biphasic layer.

The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and characterized by a considerably increased utilization of the active substance.

The invention relates to a monopolymer multifunctional sequenced cast polyurethane matrix produced simply and efficiently, by sequentially pouring various isocyanate/polyol complex phase solutions successively into a mould with alternating solidification of said phase solutions according to a defined order and respecting the polymerisation stage (after the pot life and before the demolding time) of the sequence preceding the one being cast, so as to end with the casting of the last phase solution that will go up to the demolding time thereof and thereby finish the polymerisation of the whole of the matrix. It is loaded, in its “reservoir” sequences, with naturally originating or synthesised transdermally penetrating or volatile active substances. They are medicating and therapeutic, cosmetic, phytosanitary or wellness substances, repellents, attractants, pheromones, biocides, perfumes or deodorants. At least two active substances can be loaded into the same matrix in order to act unidirectionally or in opposite directions. Said matrix is used to form different devices that adhere to the skin or any other surface, in order to deliver at least one substance in a controlled manner. Said devices are patches, patches with a plurality of active substances, replaceable plasters stuck to a textile support, active heel pads and ball pads for shoes, pheromone cards for controlling insects, self-adhesive insecticide attractant cards, or other devices equivalent in terms of structure and function.